tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Keay Nakae, 207 are a BUY (88.09%), 20 are a HOLD (8.51%), 8 are a SELL (3.4%).
Analyst Keay Nakae, currently employed at CHARDAN CAPITAL, carries an average stock price target met ratio of 40.82% that have a potential upside of 38.25% achieved within 99 days.
Keay Nakae’s has documented 408 price targets and ratings displayed on 36 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on DYN, Dyne Therapeutics at 17-Jun-2025.
Analyst best performing recommendations are on KMDA (KAMADA).
The best stock recommendation documented was for EVLO (EVELO BIOSCIENCES) at 11/1/2021. The price target of $240 was fulfilled within 4 days with a profit of $50.6 (26.72%) receiving and performance score of 66.79.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$5
$1.57 (45.77%)
$5
2 months 28 days ago
(28-Mar-2025)
4/12 (33.33%)
$1.5 (42.86%)
136
Buy
$5
$1.57 (45.77%)
$5
5 months 4 days ago
(21-Jan-2025)
0/17 (0%)
$1.79 (55.76%)
Buy
$5
$1.57 (45.77%)
$4
10 months 23 days ago
(02-Aug-2024)
2/6 (33.33%)
$1.26 (33.69%)
256
Buy
$5
$2.08 (71.23%)
3 years 4 months 23 days ago
(02-Feb-2022)
0/1 (0%)
$2.11 (73.01%)
Buy
$7
3 years 11 months 28 days ago
(28-Jun-2021)
0/4 (0%)
$3.7 (112.12%)
Which stock is Keay Nakae is most bullish on?
Which stock is Keay Nakae is most reserved on?
What Year was the first public recommendation made by Keay Nakae?
